We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-2.21%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$170M
AUM Growth
-$21.4M
Cap. Flow
-$8.68M
Cap. Flow %
-5.12%
Top 10 Hldgs %
56.85%
Holding
56
New
12
Increased
10
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$4.91M
2
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.73M
3
CLSD
Clearside Biomedical
CLSD
+$4.52M
4
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.36M
5
BPMC
Blueprint Medicines
BPMC
+$2.86M

Top Sells

Rank Stock Value
1
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$5.03M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.99M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$4.61M
4
IMMU
Immunomedics Inc
IMMU
+$3.9M
5
ZGNX
Zogenix, Inc.
ZGNX
+$2.52M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
2 Miscellaneous 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
26
Abeona Therapeutics
ABEO
$345M
$1.94M 1.14%
16,000
+12,000
+300% +$1.88M
CTMX icon
27
CytomX Therapeutics
CTMX
$745M
$1.87M 1.1%
170,000
+10,000
+6% +$121K
KA
28
DELISTED
Kineta, Inc. Common Stock
KA
$1.84M 1.08%
1,071
-15
-1% -$24.5K
HROW icon
29
Harrow
HROW
$1.44B
$1.8M 1.06%
720,000
-495,381
-41% -$1.32M
SAGE
30
DELISTED
Sage Therapeutics
SAGE
$1.79M 1.05%
+35,000
New +$1.65M
NDRM
31
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.73M 1.02%
115,000
+16,500
+17% +$309K
WGBS
32
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.58M 0.93%
+320,000
New +$1.41M
CORI
33
DELISTED
Corium International, Inc.
CORI
$1.54M 0.91%
380,000
-20,000
-5% -$99.8K
SGMO
34
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.22M 0.72%
+400,000
New +$1.46M
AKAO
35
DELISTED
Achaogen Inc
AKAO
$1.04M 0.61%
+80,000
New +$549K
OCUL icon
36
Ocular Therapeutix
OCUL
$2.38B
$783K 0.46%
+93,600
New +$726K
TRIL
37
DELISTED
Trillium Therapeutics Inc.
TRIL
$622K 0.37%
110,000
-65,000
-37% -$647K
BLRX
38
BioLineRX
BLRX
$12.1M
$230K 0.14%
417
– –
AGRX
39
DELISTED
Agile Therapeutics
AGRX
$85K 0.05%
+8
New +$112K
AFMD
40
DELISTED
Affimed
AFMD
– –
-43,000
Closed -$1.2M
AMRN
41
Amarin Corp
AMRN
$297M
– –
-35,000
Closed -$2.23M
ASRT
42
DELISTED
Assertio
ASRT
– –
-28
Closed -$41K
INDP icon
43
Indaptus Therapeutics
INDP
$155M
– –
-78
Closed -$1.03M
RARE icon
44
Ultragenyx Pharmaceutical
RARE
$2.59B
– –
-35,000
Closed -$2.48M
TENX icon
45
Tenax Therapeutics
TENX
$82M
– –
-12
Closed -$905K
GBT
46
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-200,000
Closed -$4.61M
NBRV
47
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-958
Closed -$1.69M
AMAG
48
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-15,000
Closed -$368K
IMMU
49
DELISTED
Immunomedics Inc
IMMU
– –
-1,200,000
Closed -$3.9M
PTLA
50
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-35,000
Closed -$795K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2016 Portfolio in Review

As of Q4 2016, Opaleye Management held 56 positions worth $170M, down 11% from $191M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management withdrew a net $8.68M in Q4 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA), an estimated $5.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 93% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Theravance Biopharma worth $5.04M.

  • Opaleye Management's largest Q4 2016 buy was Theravance Biopharma: 158,200 shares worth $5.04M.
  • Opaleye Management added most to Blueprint Medicines in Q4 2016, an estimated $2.86M increase.
  • Opaleye Management's biggest Q4 2016 reduction was Tvardi Therapeutics, cutting an estimated $1.78M.
  • Opaleye Management fully exited CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA) in Q4 2016, selling an estimated $5.03M.
  • Opaleye Management's ten largest holdings make up 57% of its $170M portfolio in Q4 2016.
  • Opaleye Management opened 12 new positions and closed 16 in Q4 2016.
  • Opaleye Management's portfolio value fell 11% quarter-over-quarter to $170M.

Based on Opaleye Management's 13F filing for Q4 2016, filed 21 Feb 2017.